Cover Image
市場調查報告書

Xeljanz (tofacitinib) (類風濕性關節炎) - 2023年為止的預測與市場分析

Xeljanz (tofacitinib) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 258656
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
Xeljanz (tofacitinib) (類風濕性關節炎) - 2023年為止的預測與市場分析 Xeljanz (tofacitinib) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 65 Pages
簡介

類風濕性關節炎 (RA) 是慢性自體免疫疾病,會引發關節發炎及變形。全球主要10國(美國、法國、德國、義大利、西班牙、英國、日本、澳洲、中國、印度) 患者數超過了700萬人,預測到2023年前達到850萬人。之前TNF抑制劑雖然對RA的徵兆和症狀都有效,但由於引進生技仿製藥、新生技藥品、口服的JAK抑制劑等,市場情勢正在急速變化。

本報告提供RA治療藥物──Xeljanz (tofacitinib) 之調查分析,提供您疾病概要和治療指南、競爭情形、產品資訊、銷售額預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀
  • 預後
  • QOL

第4章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療指南
    • 主要的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Xeljanz (tofacitinib)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC501DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Xeljanz (tofacitinib, formerly known as tasocitinib) is an oral, small-molecule inhibitor of JAK3 developed by Pfizer. Xeljanz is a first-in-class drug that was approved for the treatment of RA in the US in 2012, and in Japan in 2013. It is also in development for the treatment of psoriasis (as a topical and oral formulation), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, atopic dermatitis, and juvenile idiopathic arthritis in the seven major markets (7MM; US, 5EU, and Japan).

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xeljanz (tofacitinib) for the top 2 countries from 2013 to 2023.
  • Sales information covered for the US and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Xeljanz (tofacitinib) performance.
  • Obtain sales forecast for Xeljanz (tofacitinib) from 2013-2023 in top 2 countries (the US and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Xeljanz (tofacitinib)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed RA Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic and Biosimilar Erosion
  • 7.5. Primary Research - KOLs Interviewed for This Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Reviewer
    • 7.7.3. Therapy Area Director
    • 7.7.4. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Product Profile - Xeljanz
  • Table 10: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6
  • Table 11: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6
  • Table 12: Xeljanz SWOT Analysis, 2014
  • Table 13: Global Sales Forecasts ($m) for Xeljanz, 2013-2023
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
Back to Top